Anders Månsson

CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden.

Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019.

Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.